Cover Image
市場調查報告書

Probiodrug AG的產品平台分析

Probiodrug AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321991
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
Probiodrug AG的產品平台分析 Probiodrug AG - Product Pipeline Review - 2015
出版日期: 2015年04月15日 內容資訊: 英文 23 Pages
簡介

Probiodrug AG是總公司設立於德國的生物製藥企業。正在開發老年癡呆症,心血管系統發炎等相關疾病所用的小分子治療藥。

本報告提供Probiodrug AG 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Probiodrug AG 基本資料

  • Probiodrug AG 概要
  • 主要資訊
  • 企業資料

Probiodrug AG :R&D概要

  • 主要的治療範圍

Probiodrug AG :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Probiodrug AG :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Probiodrug AG :藥物簡介

  • PQ-912
  • PBDC-06
  • PQ-1565

Probiodrug AG :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Probiodrug AG :最新的開發平台資訊

Probiodrug AG :中止開發的計劃

Probiodrug AG :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06942CDB

Summary

Global Markets Direct's, 'Probiodrug AG - Product Pipeline Review - 2015', provides an overview of the Probiodrug AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Probiodrug AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Probiodrug AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Probiodrug AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Probiodrug AG's pipeline products

Reasons to buy

  • Evaluate Probiodrug AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Probiodrug AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Probiodrug AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Probiodrug AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Probiodrug AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Probiodrug AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Probiodrug AG Snapshot
    • Probiodrug AG Overview
    • Key Information
    • Key Facts
  • Probiodrug AG - Research and Development Overview
    • Key Therapeutic Areas
  • Probiodrug AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Probiodrug AG - Pipeline Products Glance
    • Probiodrug AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Probiodrug AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Probiodrug AG - Drug Profiles
    • PQ-912
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBDC-06
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PQ-1565
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Probiodrug AG - Pipeline Analysis
    • Probiodrug AG - Pipeline Products by Target
    • Probiodrug AG - Pipeline Products by Route of Administration
    • Probiodrug AG - Pipeline Products by Molecule Type
    • Probiodrug AG - Pipeline Products by Mechanism of Action
  • Probiodrug AG - Recent Pipeline Updates
  • Probiodrug AG - Dormant Projects
  • Probiodrug AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Probiodrug AG, Key Information
  • Probiodrug AG, Key Facts
  • Probiodrug AG - Pipeline by Indication, 2015
  • Probiodrug AG - Pipeline by Stage of Development, 2015
  • Probiodrug AG - Monotherapy Products in Pipeline, 2015
  • Probiodrug AG - Phase II, 2015
  • Probiodrug AG - Preclinical, 2015
  • Probiodrug AG - Pipeline by Target, 2015
  • Probiodrug AG - Pipeline by Route of Administration, 2015
  • Probiodrug AG - Pipeline by Molecule Type, 2015
  • Probiodrug AG - Pipeline Products by Mechanism of Action, 2015
  • Probiodrug AG - Recent Pipeline Updates, 2015
  • Probiodrug AG - Dormant Developmental Projects,2015
  • Probiodrug AG, Subsidiaries

List of Figures

  • Probiodrug AG - Pipeline by Stage of Development, 2015
  • Probiodrug AG - Monotherapy Products in Pipeline, 2015
  • Probiodrug AG - Pipeline by Top 10 Target, 2015
  • Probiodrug AG - Pipeline by Top 10 Molecule Type, 2015
  • Probiodrug AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top